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Transplantation of allogeneic human cardiac/stem progenitor cells (hCSC) is currently being tested in several 
phase I/II clinical trials as a novel and promising therapy for restauration of myocardial tissue function in acute 
myocardial infarction (AMI) patients. Previous findings demonstrate that these cells have an immune 
suppressive profile, interacting with different populations from the immune system, resulting in overall 
attenuation of myocardium inflammation. However, transplanted hCSCs are still recognized and cleared from 
the injured site impairing long retention times in the tissue that could be translated into a higher clinical benefit.  
In this work, different models of allogeneic hCSC/ T-lymphocyte interaction in vitro were explored, using the 
same hCSCs employed in the allogenous hCSCs transplantation phase I/II clinical trial CARE-MI, 
NCT02439398. T lymphocytes were cultured either in direct contact with hCSCs, or using transwell inserts or 
with hCSC conditioned medium.  
 
In our results, we show that IFN-γ activation is correlated with an increase in hCSC indoleamine 2,3-
dioxygenase (IDO) enzyme expression.  We also show a significant inhibition of T lymphocyte inhibition when 
cultivating human peripheral blood mononuclear cells (hPBMCs) in direct cell-cell contact, using transwells or 
with activated hCSC conditioned medium, combined with tryptophan depletion and kyurenine (a tryptophan 
metabolite) accumulation in activated hCSCs conditioned medium.    
 
These findings provide evidence, that although playing a role in the process, PDL-1 cell contact dependent 
T-regulatory cell modulation is not the exclusive neither the central mechanism involved in T-lymphocyte 
proliferation inhibition. This finding further supports the prominent paracrine-based beneficial CSC activities in 
the host tissue. 
 
Our results demonstrate for the first time that hCSCs exert an immune-suppressive effect on T lymphocyte 
proliferation through a paracrine mechanism associated with IDO enzyme mediated tryptophan metabolism.  
The knowledge generated contributes not only to a better understanding on hCSC immunomodulatory 
mechanisms, but also open new avenues in the development of new hCSC transplantation strategies in 
allogeneic settings.  
 
 
 
 
